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economics and social security were extracted. The burden was measured for “LBP-
episodes”, defined as time periods with consecutive visits to the healthcare system 
with a relevant diagnosis code, continuing until 6 months have elapsed without 
costs incurred by LBP-related visits. Results: More than 72,000 patients were iden-
tified, with over 95,000 LBP-episodes. The average episode length was 56/176 days in 
episodes without/with surgery. The mean total cost per episode was estimated at 
€ 5,453, where indirect costs constituted 68.4%, medical visits including diagnostic 
imaging 14.5%, other inpatient care 8.2%, surgery 7.9%, and pharmaceuticals 1.0%. 
In men/women, the mean total cost per episode was estimated to € 22,174/€ 24,833 
in episodes with surgery, and € 4,175/€ 3,957 in episodes without surgery. The total 
burden of LBP in Sweden in 2012 was estimated at € 704M, with a burden per capita 
of € 73. Higher age, women, comorbidities, surgery and less education were found 
to be significant predictors of higher costs. ConClusions: The societal burden of 
LBP is substantial and varies significantly between different types of patients. It 
is important to identify periods and interventions within a LBP-episode that can 
be relevantly adjusted in order to optimize cost-effectiveness of treatment, and 
also, to realize that results may be dependent on the time frame chosen for a LBP-
episode. Acknowledgements: The study was financed with an unrestricted grant 
from Medtronic.
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objeCtives: The aim of this study was to calculate the years of working life lost 
(YWLL) from early exit from work associated with Osteoarthritis (OA). Methods: 
We used data from the population-based EpiReumaPt study (Sep2011-Dec2013). 
10,661 inhabitants were surveyed to capture all cases of RD within a representa-
tive sample of the Portuguese population. We analyzed all aged 50-65 years old 
(yo), near the official retirement age. YWLL were determined for OA cases with 
premature exit from work caused by RD (self-reported) estimated as the difference 
between each participant’s age and the respective age (“observed stock”), while the 
potential YWLL (PYWLL: YWLL+“expected stock” of YWLL still to occur if there is 
no return-to-work) was the difference between official and actual retirement ages. 
We also calculated the percentage of time in inactivity (inactivity ratio= YWLL/
Active age-range[15-65yo]). We excluded all OA participants with concomitant 
inflammatory rheumatic diseases with possible impact on retirement, such as 
rheumatoid arthritis and spondylarthritis. All cases with retirement prior to 
onset of OA symptoms were also excluded. All results were based on weighted 
data. Results: The estimated prevalence of OA in the Portuguese population 
(50-64 yo) is 29.7% (knee:18.6%; hand:12.6%; hip:3.6%). Among these, 61.8% were 
out of work versus 47.6% for those without OA (p= 0.004), which potentially led to 
162,735 YWLL (95 per 1000 inhabitants). Early retirement contributed the most for 
these YWLL (58%; 94,432 YWLL), followed by unemployment (35%; 57,209 YWLL) 
and disability pensions (7%; 11,094 YWLL). Women accounted for 80% of these 
YWLL (153 per 1000 female inhabitants). A total of 161,621 PYWLL were estimated 
if early retirement is considered and 369,839 PYWLL for all forms of exit from 
work. The mean YWLL and PYWLL inactivity ratios were 16% and 30%, respec-
tively. ConClusions: We estimated a considerable amount of working life years 
losses associated with OA in Portugal.
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objeCtives: To estimate the economic burden of hip fractures in Norway under 
different assumptions on the future demographic and fracture rate develop-
ment. Methods: Based on population projections from Statistics Norway and 
estimated fracture rates, we projected the future number of hip fractures in the 
period 2014-2040. We projected assuming both a low, medium and high population 
increase. We estimated fracture rates based on data from the hip fracture database 
of the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS), using data for 
the period 1999 to 2008. We predicted future fracture rates under three scenarios: 
assuming a constant future rate, assuming a continued decline in the fracture 
rate and assuming a continued, but somewhat reduced decline. We considered 
a medium population growth and a reduced decline as the most likely scenario. 
To the estimated number of fractures we added the cost of hip fracture surgery 
and other health and social care cost related to hip fractures from a recent Lancet 
publication. Results: The projected future cost in the period from 2014 to 2040 
varies from a 14% increase in the best-case scenario to 121% increase in cost in 
the worst-case scenario, with a 65% increase as the most likely estimate. From 
a hospital perspective, the costs could increase from € 108M to either € 119M in a 
best-case scenario or € 235M in a worst-case scenario. If we include not only the 
cost of the primary hospitalization, but also the cost of other health and social 
services (e.g. long term nuring home care) related to the fracture, the cost impact 
will increase from € 341M to € 388M either or € 766M ConClusions: Our study 
indicates that the number and cost of hip fractures is likely to increase until 2040, 
but the magnitude of the impact is very much dependent on demographic change 
and fracture rate development.
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mean age of 65.9 (±10.5) years, 62.1% female, and 88.2% retired. Annual mean 
all-cause cost was $2,466 per patient with osteoporosis-related cost accounting 
for 53.8%. For osteoporosis-related health services, 33.2% of patients experienced 
≥ 1 hospitalization with mean length of stay of 18.0 (±14.4) days and mean cost of 
$2,913 per admission, and 83.2% of patients experienced ≥ 1 outpatient visit with 
mean (±SD) number of visits 7.4 (±8.7) and mean cost $17 per visit. The medical 
device cost was the largest component (38.5%) of osteoporosis-related cost, fol-
lowed by drug cost (31.1%) and examination cost (11.7%). The regression model 
revealed that osteoporosis-related cost tended to increase with age, patients with 
hip, vertebral, lower leg and multiple fractures were more likely to have a higher 
cost. ConClusions: Costs for patients with osteoporotic fractures were consid-
erable in Tianjin China, driven mainly by osteoporosis-related hospitalizations. 
Efforts focused on reducing the utilization of inpatient services and increasing 
efforts to lower the fracture risks may have the potential to lighten the economic 
burden of osteoporotic fractures in China.
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objeCtives: The aim of this study was to assess the indirect costs caused by 
absenteeism associated with ankylosing spondylitis (AS) from the perspective of 
the Social Insurance Institution (ZUS) in Poland. Methods: The estimates were 
based on data from the year 2013 concerning absence from work due to the ill-
ness (sick leave) the amount of short-term disability, the sufferers of which claim 
rehabilitation benefit, and the amount of long-term disability (permanent or fixed 
time), the sufferers of which claim disability pension. Costs were calculated taking 
into account Gross Domestic Product (GDP) per capita equaled € 10 278, Gross Value 
Added (GVA) per worker equaled € 24 680 and Gross Income (GI) per worker equaled 
€ 7 339 were presented in 2013 prices. Results: Total indirect costs of AS in the year 
2013 calculated using GDP per capita, GVA and GI per worker in Poland were € 24 416 
394, € 58 631 008 and € 17 435 690, respectively. The highest component of indirect 
costs of AS was permanent long-term disability (68%). Sick leave and short-term 
disability costs constitute 12% and 4% of total indirect costs of AS, respectively. In 
2013 Poland’s Social Insurance Institution database reported 3 400 patients that 
had 7 137 sick leave episodes, 225 short-term disability episodes and 198 long-term 
disability episodes. Indirect costs per patient associated with sick leave were € 894, 
€ 2 147 and € 639 calculated using GDP, GVA and GI, respectively. Indirect costs per 
patient associated with short-term disability were € 259, € 622 and € 185 respectively 
and associated with long-term disability were as high as € 6 028, € 14 474 and € 4 304, 
respectively. ConClusions: AS in Poland generated high indirect costs. The main 
component was permanent long-term disability; short-term disability generated 
lower costs of lost productivity. The highest cost per patient was generated by per-
manent long-term disability.
PMS47
the CoSt of rehuMatoid diSeaSeS in itaLY: anaLYSiS froM an itaLian 
adMiniStrative dataBaSe
Furneri G1, Iannazzo S2, Berti V3, Fregonara Medici M4, Parisi S5, Fusaro E5
1EBMA Consulting, Melegnano, Italy, 2SIHS Health Economics Consulting, Torino, Italy, 3CSI 
Piemonte, Torino, Italy, 4Regione Piemonte, Torino, Italy, 5Azienda Ospedaliero Universitaria Città 
della Salute e della Scienza di Torino, Torino, Italy
objeCtives: Chronic Inflammatory Rheumatic Diseases (CIRD), especially 
Rheumatoid Arthrits and Spondyloarthritis, are systemic inflammatory disorders 
significantly affecting patients’ quality of life. Disability and comorbidity associ-
ated to such conditions trigger high costs for healthcare systems and society. This 
analysis aims to measure direct costs in patients receiving pharmacological treat-
ment. Methods: Using administrative healthcare claims from the Piedmont region 
in the North-West of Italy, we detected CIRD patients who, during the period Jan 2008 
- Dec 2010, had > 1 disease-modifying antirheumatic drug (DMARD) prescription, 
either synthetic (e.g. methotrexate) or biologic (e.g. infliximab). RD was confirmed if 
patients had > 1 hospital diagnosis of CIRD (rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis, ICD-9 codes : 714.0, 696.0, 720.0) and/or an exemption code 
for similar diagnoses. Each patient was followed up from first DMARD prescription 
(index date) for three years or until death. Results: In the selected period N= 12,455 
patients with CIRD diagnosis received DMARD. Patients were mainly female (58.1%), 
with a mean age of 55.3 (+17.4) years. Direct annual costs were € 6,983, € 4,974, € 5,178, 
during Year 1, 2, 3. The composition of average annual costs was: € 1,531 (26.8%) 
for hospital costs and emergency room costs, € 163 (2.9%) for synthetic DMARDs, 
€ 2,188 (38.3%) for biologic DMARDs, € 985 (17.2%) for concomitant medications, € 845 
(14.8%) for ambulatory visits. N= 4,670 (37.5%) received biologic therapy during the 
follow-up. ConClusions: Chronic Inflammatory Rheumatic Diseases determine 
a relevant economic burden for healthcare services, because of significant epide-
miological impact and high per-patient costs. Costs are significantly high at every 
stage of disease, both at time of diagnosis, and over time.
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objeCtives: The objective of this study was to estimate the direct and indirect 
costs of low back pain with/without radiant pain (LBP) in Sweden using the concept 
of “LBP-episode”, and to identify the variation of these across different patients 
groups. Methods: Patients visiting healthcare providers, or receiving health insur-
ance benefits, with a LBP-diagnosis in the region of Västra Götaland in 2008-2012 
were identified in the administrative database VEGA. Data from additional Swedish 
national registers including inpatient and outpatient care, drug prescriptions, socio-
